Crescent Capital Consulting’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Crescent Capital Consulting’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$11K	Hold	100	–	–	﹤0.01%	389
2021 Q3	$13K	Sell	100 -400	-80%	-$51.5K	﹤0.01%	406
2021 Q2	$68K	Buy	500 +100	+25%	+$13.1K	0.01%	253
2021 Q1	$54K	Hold	400	–	–	0.01%	275
2020 Q4	$56K	Buy	+400	New	+$51.2K	0.01%	242

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Crescent Capital Consulting's XBI Position: Q4 2021 in Review

Crescent Capital Consulting held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q4 2021 at 100 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #389.

Crescent Capital Consulting first reported a position in XBI in Q4 2020 and has held it in 5 quarters since. The position peaked at $68K in Q2 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q4 2021.

Crescent Capital Consulting held 100 shares of State Street SPDR S&P Biotech ETF worth $11K as of Q4 2021.
Crescent Capital Consulting left its State Street SPDR S&P Biotech ETF share count unchanged in Q4 2021.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #389 holding.
Crescent Capital Consulting first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and has held it in 5 quarters since.
Crescent Capital Consulting's State Street SPDR S&P Biotech ETF position peaked at $68K in Q2 2021.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.